Introduction
============

It is now well established that the complex microbial communities that inhabit the gastrointestinal tract (GIT) play a vital role in maintaining gut health and homeostasis although the precise molecular mechanisms involved are as yet poorly understood (reviewed by [@b43]; [@b15]). Bifidobacteria, which belong to the phylum *Actinobacteria*, constitute a significant bacterial group in the human GIT and have attracted a lot of attention as a result of their perceived positive contribution to the functionality of the GIT. The health‐promoting effects attributed to (certain strains of) bifidobacteria include enhancement of immune function, improvement of colonic integrity, reduction of incidence and duration of intestinal infections, downregulation of allergic responses and stimulation of digestion and elimination (reviewed by [@b33]). These positive attributes have led to their inclusion in functional foods ([@b1003]).

Prebiotics are defined as 'selectively fermented food ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confer benefits upon host well being and health' ([@b14]). A prebiotic may also be included in a probiotic‐containing functional food, and in such cases the synergistic combinations of pro‐ and prebiotics are termed synbiotics ([@b27]). Carbohydrates that have been shown to exert prebiotic effects include those from whole grain wheat, fructo‐oligosaccharides, galacto‐oligosaccharides and type II arabinogalactans (reviewed by [@b14]; [@b1004]). Together probiotics and prebiotics share a unique role in human nutrition, largely focusing on the manipulation of populations and/or activities of the bacteria that colonize the GIT. The development of functional foods containing prebiotics and/or probiotics, which can change the composition and/or activity of the microbiota, in a predictable manner, represents a major scientific challenge for both the pharma and food industries. The recent explosion in the availability of genome sequences of gastrointestinal microbes should allow the selection of novel, perhaps more selective prebiotics and will also be pivotal in attaining a fundamental understanding of the probiotic effect ([@b37])

(Arabino)galactans are an abundant, plant‐derived carbohydrate source derived from pectin. Despite daily consumption of galactan through ingestion of fruit, vegetables and cereals, plant cell wall polysaccharides have not been extensively exploited as a potential source of prebiotics. Pectin consists of 'smooth' regions of α‐1,4‐galacturonic acid (homogalacturonan) and 'hairy' regions of rhamnogalacturonan. Two types of arabinogalactan side‐chains are present in rhamnogalacturonan; type I consists of a chain of β‐1,4‐linked [d]{.smallcaps}‐galactopyranose linkages, while type II contains a backbone of β‐1,3‐linked [d]{.smallcaps}‐galactopyranose residues that can be substituted with β‐1,6‐linked [d]{.smallcaps}‐galactopyranose residues. Both types can furthermore be substituted with β‐1,3‐linked arabinofuranose chains ([@b6]). Type I (arabino)galactan is degraded by bacteria using a combination of β‐1,4‐endogalactanase and β‐galactosidase activities, where the former enzyme cleaves within the galactan moiety of its substrate releasing [d]{.smallcaps}‐galacto‐oligosaccharides. Bacterial β‐1,4‐endogalactanases are reported to release mainly galactotriose and galactotetraose, while some may also release galactobiose ([@b7]). Genes encoding β‐1,4‐galactanase activity have been characterized from *Bacillus subtilis* ([@b19]), *Peudomonas fluorescens* ([@b2]), *Erwinia chrysanthemi* ([@b9]), *Termotoga maritime* ([@b42]) and *Bifidobacterium longum* ([@b10]). [@b8]) observed that *B. longum* was incapable of growth on type II larch wood arabinogalactan; however, crossfeeding of *B. longum* was observed when grown in co‐culture with *Bacteroides thetaiotaomicron.* More recently, [@b10]) extensively characterized the *gal*A gene, encoding a β‐1,4‐endogalactanase, from *B. longum* NCC490. Here we report on the endogalactanase‐encoding gene locus from *Bifidobacterium breve* UCC2003, which encodes a complete functional system for galactan utilization by this strain. Our work shows that galactan utilization by *B. breve* UCC2003 requires an extracellular endogalactanase, encoded by *galA*, to degrade galactan mainly into galacto‐trisaccharide, which is then internalized by a dedicated ABC transport system and hydrolysed to galactose by a specific β‐galactosidase encoded by *gal*G. Furthermore, we present data that implicate the LacI‐type regulator, GalR, in the regulation of promoters upstream of the endogalactanase‐encoding gene, *galA*, and the first gene, *galC*, of the ABC transport system in a galactotriose/biose‐dependent manner.

Results
=======

Growth of bifidobacterial strains on arabinogalactan, pectic galactan, galactan and glucose
-------------------------------------------------------------------------------------------

In order to establish if bifidobacteria are capable of (arabino)galactan metabolism, growth in Modified Rogosa medium supplemented with arabinogalactan derived from larch wood (backbone of β‐1,3‐linked [d]{.smallcaps}‐galactopyranose residues that can be substituted with β‐1,6‐linked [d]{.smallcaps}‐galactopyranose residues and can be further substituted with β‐1,3‐linked arabinofuranose chains), potato‐derived pectic arabinogalactan (β‐1,4‐linked [d]{.smallcaps}‐galactopyranose linkages substituted with β‐1,3‐linked arabinofuranose chains), potato galactan (β‐1,4‐linked [d]{.smallcaps}‐galactopyranose chains) or glucose was assessed for 34 bifidobacterial strains most of which are human‐derived and which represent nine bifidobacterial species. Growth assessment by measuring optical density following 24 h of anaerobic growth at 37°C revealed that all bifidobacterial strains grew well on glucose, reaching OD~600~ values in excess of 1.0. In contrast, none of the bifidobacterial strains tested grew well on larch arabinogalactan, while just 11 of the 34 strains tested were able to reach an OD~600~ higher than 1.0 when grown on potato‐derived pectic arabinogalactan or galactan as the sole carbohydrate source ([Fig. 1](#f1){ref-type="fig"}). Interestingly, of these latter 11 strains, six belong to the *B. breve* species, including *B. breve* UCC2003 ([Fig. 1](#f1){ref-type="fig"}). These data indicate that only certain bifidobacteria can metabolize (arabino)galactan derived from potato, and that this sugar may thus represent a selective growth substrate for such strains. Furthermore, our data show that (arabino)galactan derived from larch wood did not support growth of the bifidobacteria tested in this study, although it cannot be ruled out that *in vivo* intestinal communities may contain bifidobacteria that may be capable of fermenting this carbohydrate.

![Final optical density (OD~600~) values obtained following 24 h growth of various bifidobacterial strains in modified MRS containing 0.5% glucose, potato galactan, potato‐derived pectic arabinogalactan or arabinogalactan derived from larch wood as the sole carbon source. The results are mean values obtained from three separate experiments.](mbt0004-0403-f1){#f1}

Genome response of *B. breve* UCC2003 to growth on Galactan
-----------------------------------------------------------

In order to investigate which genes may be involved in galactan metabolism in *B. breve* UCC2003, global gene expression was determined by microarray analysis during growth of this bifidobacterial strain on potato galactan and compared with its expression pattern when grown on ribose. Total RNA was isolated from *B. breve* UCC2003 cultures grown on potato galactan or ribose as sole carbohydrate source. Analysis of the DNA microarray data revealed that the expression of five adjacent genes was significantly upregulated (fold change \> 15.0, *P* \< 0.001; [Table 2](#t2){ref-type="table"}). These genes constitute the galactan metabolism cluster (see below) and were designated *gal*C, *gal*D, *galE*, *gal*G, *gal*R and *gal*A ([Fig. 2](#f2){ref-type="fig"}), of which the latter had previously been shown to be involved in galactan metabolism ([@b21]). To confirm the microarray results, quantitative RT‐PCR (qRT‐PCR) analysis was performed using primer pairs representing individual genes of the gal gene cluster (Table S1). cDNA templates were derived from RNA isolated from *B. breve* UCC2003 following growth on galactan or ribose. As expected, the *gal*CDEG and *gal*A genes were shown to be upregulated, consistent with the microarray results ([Table 2](#t2){ref-type="table"}).

###### 

Effect of potato galactan on the transcriptome of *B. breve* UCC2003.

  Locus tag_gene     Putative function                        Galactan[a](#t2n1){ref-type="table-fn"}   QRT‐PCR[b](#t2n2){ref-type="table-fn"}
  ------------------ ---------------------------------------- ----------------------------------------- ----------------------------------------
  bbr_0417\_*gal*C   Solute binding protein                   **37.6**                                  **26.62**
  bbr_0418\_*gal*D   Sugar permease protein                   **20.0**                                  **18.0**
  bbr_0419\_*gal*E   Sugar permease protein                   **19.3**                                  **15.6**
  bbr_0420\_*gal*G   β‐galactosidase GH 42 family             **17.8**                                  **15.0**
  bbr_0421\_*gal*R   Transcriptional regulator, LacI family   6.6                                       3.0
  bbr_0422\_*gal*A   Endogalactanase                          **28.9**                                  **25.3**

Expression ratios presented in bold have a Bayesian *P*‐value \< 0.001 according to the Cyber‐*T*‐test ([@b1002]).

Expression ratios of selected genes quantified by QRT‐PCR. cDNA templates were derived from RNA samples of *B. breve* UCC2003 culture grown on ribose as a comparator.

![Comparison of the gal locus of *B. breve* UCC2003 with corresponding putative galacto‐oligosaccharides/galactan utilization loci from other bifidobacteria. Each solid arrow indicates an open reading frame. The lengths of the arrows are proportional to the length of the predicted open reading frame and the gene locus name, which is indicative of its putative function, is indicated within the arrow. Orthologs are marked with the same colour while the amino acid identity of each predicted protein is indicated as a percentage relative to its equivalent protein encoded by *B. breve* UCC2003. The bent arrows indicate the *gal*c and *gal*A promoters; the lollipop sign designates putative *rho*‐independent terminator region.](mbt0004-0403-f2){#f2}

Genetic organization of the putative galactan utilization cluster
-----------------------------------------------------------------

Our presumption, based on microarray results, that the genes upstream of *gal*A were also involved in galactan metabolism was substantiated by their conservation among sequenced bifidobacterial genomes. The *gal* gene cluster ([Fig. 2](#f2){ref-type="fig"}) contains *gal*A, which is a clear homologue of the *B. longum* NCC490 *gal*A gene, which encodes a characterized endogalactanase ([@b10]). The *B. breve* UCC2003 *gal*A gene is located downstream of a gene, *gal*R, predicted to encode a LacI‐type transcriptional regulator and representing the presumed regulator of the *gal*CDEGR operon and *gal*A of *B. breve* UCC2003 (see below). The *galC, galD* and *galE* genes, which together are believed to specify an ABC‐type uptake system for galacto‐oligosaccharides, encode a galacto‐oligosaccharide‐binding and two permease proteins respectively. Interestingly, a gene encoding a putative ATP‐binding protein is present upstream of *galC*, although the array data indicate that this gene is not under galactan‐inducible control (data not shown), and it may therefore be that this gene specifies a general ATP‐binding protein involved in providing energy to multiple ABC‐type sugar uptake systems ([@b26]; [@b39]). The *gal*G gene is predicted to encode a putative β‐galactosidase, which belongs to the glycosyl hydrolase family GH42 ([@b3]), and is predicted to be responsible for hydrolysis of internalized galacto‐oligosaccharides to galactose monomers. Comparative genome analysis showed that the *B. breve* UCC2003 *gal* gene cluster is most similar to the similarly organized putative endogalactanase gene clusters of *B. longum* strains DJ010A and NCC2705 ([Fig. 2](#f2){ref-type="fig"}). In *B. longum* ssp. *infantis* strains CCUG52486 and ATTCC15697 the *gal*A gene would appear to have undergone an internal deletion with the loss of the GH53 domain, as the putative proteins encoded by blon_0440 and rblf0255 are much shorter than GalA and show similarity only to the C‐terminal putative calcium‐binding extension of GalA. The absence of a functional GalA homologue in strains CCUG52486 and ATTCC15697 is consistent with their inability to grow on galactan as sole carbohydrate source (data not shown). Interestingly and consistent with the observation that *Bifidobacterium dentium* Bd1 is incapable of growth on galactan ([Fig. 1](#f1){ref-type="fig"}), analysis of the Bd1 genome sequence ([@b38]) established that this strain lacks a *gal*A homologue. In contrast, *B. dentium* ATCC27678 can metabolize potato galactan (data not show) and as expected encodes an endogalactanase, although with a different domain organization compared with its counterparts encoded by *B. breve* or *B. longum*, as it contains two GH53 domains, where in each domain the two catalytic glutamate residues characteristic of GH53 enzymes can be identified. A similar domain organization is present in an endogalactanase encoded by *Bacillus coagulans* 36D1 ([@b4]). Interestingly, the *B. dentium* ATCC27678 *gal*A homologue (encoded by *bde\_*1038) is at a distinct location in the chromosome and not located adjacent to other homologues of the *B. breve* UCC2003 *gal* locus in this strain. No obvious *gal*A homologue or homologues encoding the presumed *gal*CDE ABC transporter components are present in the *Bifidobacterium adolescentis* strains DSM20083 or L32‐2, although both strains harbour clear homologues of the β‐galactosidase‐encoding gene *gal*G and the associated LacI‐type regulator encoding gene, *gal*R ([Fig. 2](#f2){ref-type="fig"}). The presence of the *galA* gene in *B. breve* UCC2003 had previously been shown to be essential for the ability of this strain to metabolize galactan ([@b21]). The link between the presence of a *galA* homologue and the ability to metabolize galactan was confirmed by comparative genome hybridization using *B. breve* UCC2003‐based microarrays, demonstrating that tested *B. breve* strains, which are either capable or incapable of growth on galactan ([Fig. 1](#f1){ref-type="fig"}), contain or lack DNA sequences with significant identity to *galA*, respectively, although all these strains contain sequences that are homologous to the *galCDEGR* genes (A. Zomer, M. Ventura, B. Kearney, F. Turroni, M. O\'Connell Motherway and D. Van Sinderen, unpubl. data).

The C‐terminal domain of GalA is not required for growth on galactan
--------------------------------------------------------------------

The C‐terminal extension specified by the available *galA* homologues in bifidobacteria is not observed in GH53 enzymes from other bacterial strains. [@b10]) have speculated that this C‐terminal extension may be a calcium‐binding domain, which may have a role in cell envelope anchoring of GalA, consistent with the presence of a possible cell wall anchoring motif (LSNTG) at the C‐terminus of GalA. To establish the role, if any, of this C‐terminal extension in galactan metabolism a *gal*A insertion mutant was constructed in such a way that the insertion caused the separation of the GH53‐encoding domain of *gal*A from the 3′‐end of the *gal*A gene. The resulting mutant strain, which was designated UCC2003‐galA‐967 and which was expected to express a truncated GalA (amino acids 1 to 443) lacking the C‐terminal domain, was still capable of growth on galactan as its sole carbohydrate source thereby indicating that the C‐terminal extended structure of GalA is not necessary for the enzyme\'s activity, a notion which is further substantiated below.

Substrate specificity of recombinant GalA and GalG from *B. breve* UCC2003
--------------------------------------------------------------------------

In order to verify that the GH53 domain of GalA is sufficient for galactan metabolism and establish a role for the putative β‐galactosidase‐encoding gene, *gal*G, we individually cloned the complete *gal*A gene, a truncated version of *gal*A, encoding just the GH53 domain‐encoding section (generating the same truncated *galA* as was created for the UCC2003‐galA‐967 mutant described above; for details see *Experimental procedures*), and *gal*G in the nisin‐inducible expression vector pNZ8150 to generate pNZ‐galA, pNZ‐galAT and pNZ‐galG respectively (See *Experimental procedures*). The His~10~‐tagged endogalactanase GalA, truncated endogalactanase (designated as GalAT) and β‐galactosidase GalG proteins were each overexpressed and purified from the soluble cell extract fraction of *Lactococcus lactis* NZ9000 harbouring the recombinant plasmids pNZ‐galA, pNZ‐galAT or pNZ‐galG by means of metal chelate affinity chromatography. SDS‐PAGE analysis of GalA, GalAT and GalG revealed for each protein a single band at an apparent molecular mass of approximately 93 kDa, 44.6 kDa and 79 kDa, respectively, which is in agreement with their expected size as calculated from the recombinant *gal*A and *gal*G gene sequences (data not shown). The end products formed by the hydrolysis of galactan following incubation with the purified endogalactanase or truncated endogalactanase were analysed by HP‐TLC ([Fig. 3](#f3){ref-type="fig"}). Consistent with the observations of [@b10]) the results clearly demonstrate that both the endogalactanase and the C‐terminally truncated endogalactanase can liberate galacto‐oligosaccharides, predominantly galactotriose from galactan ([Fig. 3](#f3){ref-type="fig"}, lanes 3 and 5). Upon addition of GalG to the reaction mix the galactotriose is further hydrolysed to the monosaccharide galactose ([Fig. 3](#f3){ref-type="fig"}, lanes 4 and 6). Under the conditions tested GalG was incapable of hydrolysing lactose to any significant degree, but instead showed a preference for galactotriose/biose ([Fig. 3](#f3){ref-type="fig"}, lanes 8 and 9). Collectively, these results demonstrate that the endogalactanase gene cluster encodes an endogalactanase for the extracellular metabolism of galactan, and that *gal*G specifies a β‐galactosidase that cleaves β1‐4 linkages in galactotriose/biose.

![Substrate specificity of GalA, GalAT or GalG as determined by HPTLC. Lane 3--6 contain hydrolysis products of potato galactan following incubation with GalA (lane 3), GalA plus GalG (lane 4), GalAT (lane 5), GalAT plus GalG (lane 6). The hydrolysis products of galactobiose and lactose following incubation with GalG are in lanes 8 and 9 respectively. Carbohydrate standards (lanes 1 and 10) are listed to the left and right of the panel, while lanes 2 and 7 contain potato galactan and galactobiose respectively.](mbt0004-0403-f3){#f3}

Disruption of the GalC and GalG encoding genes
----------------------------------------------

In order to establish if disruption of particular genes from the *gal*CDEGR gene cluster in *B. breve* UCC2003 would result in loss of this strain\'s ability to metabolize galactan, insertion mutants in the *galC* and *galG* genes were generated, resulting in strains *B. breve* UCC2003‐galC‐701 and UCC2003‐galG‐420 respectively ([Table 1](#t1){ref-type="table"}). To verify the expected galactan‐negative phenotype of these insertion mutants, strains UCC2003 (wild type), UCC2003‐galC‐701 and UCC2003‐galG‐420 were analysed for their ability to grow in mMRS supplemented with galactan or glucose (positive control) as the sole carbon source. As expected, and in contrast to the wild type, the *B. breve* UCC2003‐galC and UCC2003‐galG insertion mutants were shown to be incapable of growth on galactan as the sole carbon source ([Fig. 4](#f4){ref-type="fig"}). We predict that the *gal*C disruption in *B. breve* UCC2003‐galC is likely to have a polar effect on the transcription of the downstream genes of the *galCDEGR* operon. To demonstrate that the protein products of this ABC transporter gene cluster are uniquely necessary for the transport of the galacto‐oligosaccharides generated through hydrolysis of galactan by GalA in *B. breve* UCC2003, complementation experiments were performed. The β‐galactosidase‐encoding gene, *gal*G, was expressed under the control of the p44 promoter on pCIB‐p44 in *B. breve* UCC2003‐galC and UCC2003‐galG (see *Experimental procedures*). Expression of GalG in UCC2003‐galG restored the ability of this mutant strain to grow on galactan as a sole carbohydrate source, while expression of GalG in *B. breve* UCC2003‐galC did not restore the ability of this strain to grow on galactan ([Fig. 4](#f4){ref-type="fig"}). This complementation experiment provides supporting evidence that the ABC transport system, encoded by *gaI*CDE, is the sole transporter of galacto‐oligosaccharides derived from galactan in *B. breve* UCC2003 and that the β‐galactosidase specified by *gal*G is essential for the intracellular metabolism of the galacto‐trisaccharides derived from GalA activity.

###### 

Bacterial strains and plasmids used in this study.

  Strains and plasmids                         Relevant features                                                                                                                                        Reference or source
  -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Strains                                                                                                                                                                                               
   *Escherichia coli* strains                                                                                                                                                                           
    *E. coli* EC101                            Cloning host, repA^+^ km^r^                                                                                                                              [@b12])
    *E. coli* EC101‐pNZ‐M.BbrII + M.BbrIII     EC101 harbouring pNZ8048 derivative containing *bbrIIM* and *bbrIIIM*.                                                                                   [@b21])
   *Lactococcus lactis* strains                                                                                                                                                                         
    *L. lactis* NZ9000                         MG1363, *pep*N::*nis*RK, nisin‐inducible overexpression host                                                                                             [@b1001])
    *L. lactis* NZ9000‐ pNZ‐galA               NZ9000 containing pNZ‐galA                                                                                                                               This study
    *L. lactis* NZ9000‐ pNZ‐galAT              NZ9000 containing pNZ‐galAT                                                                                                                              This study
    *L. lactis* NZ9000‐ pNZ‐galG               NZ9000 containing pNZ‐galG                                                                                                                               This study
    *L. lactis* NZ9000‐ pNZ‐galR               NZ9000 containing pNZ‐galR                                                                                                                               This study
   *Bifidobacterium* sp. strains                                                                                                                                                                        
    *B. breve* UCC 2003                        Isolate from nursling stool                                                                                                                              [@b16])
    *B. breve* UCC2003‐galA‐967                pORI19‐tet‐galA‐967 insertion mutant of UCC2003                                                                                                          This study
    *B. breve* UCC2003‐galG‐410                pORI19‐tet‐galG‐410 insertion mutant of UCC2003                                                                                                          This study
    *B. breve* UCC2003‐galC‐701                pORI19‐tet‐galC‐701 insertion mutant of UCC2003                                                                                                          This study
    *B. breve* UCC 2004                        Isolate from human faeces                                                                                                                                UCC
    *B. breve* UCC 2005                        Isolate from human faeces                                                                                                                                UCC
    *B. breve* UCC 2007                        Isolate from human faeces                                                                                                                                UCC
    *B. breve* JCM 7017                        Isolate from human faeces                                                                                                                                JCM
    *B. breve* JCM 7019                        Isolate from infant faeces                                                                                                                               JCM
    *B. breve* NCFB 2257                       Isolate from infant intestine                                                                                                                            NCFB
    *B. breve* NCFB 2258                       Isolate from infant intestine                                                                                                                            NCFB
    *B. breve* NCTC 11815                      Isolate from infant intestine                                                                                                                            NCTC
    *B. breve* CCUG 43878                      Isolate from human faeces                                                                                                                                CCUG
    *B. adolescentis* CIP 64.61                Isolate from human intestine                                                                                                                             CIP
    *B. adolescentis* DSM 20083                Isolate from human intestine                                                                                                                             DSM
    *B. adolescentis* NCFB 2229                Isolate from human intestine                                                                                                                             NCFB
    *B. adolescentis* NCFB 2204                Isolate from human intestine                                                                                                                             NCFB
    *B. adolescentis* LMG 10502                Isolate from human intestine                                                                                                                             LMG
    *B. animalis* JCM 20097                    Isolate from calf faeces                                                                                                                                 JCM
    *B. animalis* DSM 20105                    Isolate from chicken faeces                                                                                                                              DSM
    *B. bifidum* NCIMB 8810                    Isolate from human intestine                                                                                                                             NCIMB
    *B. bifidum* LMG 11041                     Isolate from animal intestine                                                                                                                            LMG
    *B. dentium* Bd1                           Isolate from human dental caries                                                                                                                         [@b38])
    *B. dentium* ATCC 27678                    Isolate from human dental caries                                                                                                                         ATCC
    *B. longum* JCM 7050                       Isolate from human faeces                                                                                                                                JCM
    *B. longum* JCM 7052                       Isolate from human faeces                                                                                                                                JCM
    *B. longum* JCM 7053                       Isolate from infant faeces                                                                                                                               JCM
    *B. longum* JCM 7056                       Isolate from infant faeces                                                                                                                               JCM
    *B. longum* CIP 64.63                      Isolate from infant intestine                                                                                                                            CIP
    *B. longum* CCUG 30698                     Isolate from human abdomen                                                                                                                               CCUG
    *B. longum* NCIMB 8809                     Isolate from human faeces                                                                                                                                NCIMB
    *B. longum* CCUG 15137                     Isolate from human                                                                                                                                       CCUG
    *B. longum/infantis* CCUG 18157            Isolate from human faeces                                                                                                                                CCUG
    *B. longum* subsp. *infantis* CCUG 52486   Isolate from human faeces                                                                                                                                CCUG
    *B. longum* subsp. *infantis* ATCC 15697   Isolate from human faeces                                                                                                                                ATCC
    *B. infantis* NCDO 2205                    Isolate from infant intestine                                                                                                                            NCDO
    *B. pseudocatenulatum* LMG 10505           Isolate from infant faeces                                                                                                                               LMG
    *B. pseudocatenulatum* NCIMB 8811          Isolate from infant faeces                                                                                                                               NCIMB
    *B. pseudolongum* NCIMB 2244               Isolate from swine faeces                                                                                                                                NCIMB
    *B. pseudolongum* DSM 20095                Isolate from chicken faeces                                                                                                                              DSM
    *B. glodosum* JCM 5820                     Isolate from animal rumen                                                                                                                                JCM
    *B. glodosum* JCM 7092                     Isolate from bovine rumen                                                                                                                                JCM
  *  B. thermophilum* JCM 7027                 Isolate from swine faeces                                                                                                                                JCM
  Plasmids                                                                                                                                                                                              
   pNZ8150                                     Cm^r^, nisin‐inducible translational fusion vector                                                                                                       [@b18])
   pNZ‐galA                                    Cm^r^, pNZ8150 derivative containing translational fusion of *gala*‐encoding DNA fragment without signal sequence to nisin‐inducible promoter            This study
   pNZ‐galAT                                   Cm^r^, pNZ8150 derivative containing translational fusion of truncated *gal*A‐encoding DNA fragment (from bases 90 to 1330)to nisin‐inducible promoter   This study
   pNZ‐galG                                    Cm^r^, pNZ8150 derivative containing translational fusion of *gal*G‐encoding DNA fragment without signal sequence to nisin‐inducible promoter            This study
   pNZ‐galR                                    Cm^r^, pNZ8150 derivative containing translational fusion of *gal*R‐encoding DNA fragment without signal sequence to nisin‐inducible promoter            This study
   pNZ44                                       pNZ8048 containing constitutive p44 promoter from Lactococcal chromosome                                                                                 [@b17])
   pSKEM                                       *E. coli* bifidobacterial shuttle vectoe harbouring pCIBA089 rep                                                                                         [@b5])
   pCIB‐p44                                    Complementation vector; pNZ44 where repA has been replaced with pCIBA089 rep                                                                             This study
   pCIB‐p44‐galG                               pCIB‐p44 derivative with *gal*G transcriptionally fused to p44 promoter                                                                                  This study
   pAM5                                        pBC1‐puC19‐Tc^r^                                                                                                                                         [@b1])
   pORI19                                      Em^r^, repA^‐^, ori^+^, cloning vector                                                                                                                   [@b12])
   pORI19‐tet‐galA                             Internal 967 bp fragment of *galA* and tetW cloned in pORI19                                                                                             This study
   pORI19‐tet‐galG                             Internal 410 bp fragment of *galG* and tetW cloned in pORI19                                                                                             This study
   pORI19‐tet‐galC                             Internal 701 bp fragment of *galA* and tetW cloned in pORI19                                                                                             This study

ATCC, American type culture collection; CCUG, Culture Collection of the University of Goteborg; CIP, Collection de l\'Institut Pasteur; DSM, German Collection of Microorganisms and Cell Cultures; JCM, Japan Collection of Microorganisms; LMG, Belgian Co‐ordinated Collection of Microorganisms; NCDO, National Collection of Dairy Organisms; NCFB, National Collection of Food Bacteria; NCIMB, National Collection of Industrial and Marine Bacteria; NCTC, National Collection of Type Cultures; UCC, University College Cork Culture Collection.

![Growth profile analysis of *B. breve* UCC2003, UCC2003‐galC, UCC2003‐galG and mutant strains harbouring pCIB‐p44 (control) or pCIB‐p44‐galG in modified rogosa broth supplemented with potato galactan or glucose.](mbt0004-0403-f4){#f4}

Identification of the transcription start site of *gal*A and *gal*C
-------------------------------------------------------------------

From the genetic organization ([Fig. 2](#f2){ref-type="fig"}) and the observed expression pattern ([Table 2](#t2){ref-type="table"}) of the *gal* locus it was deduced that this locus contained at least two galactan‐inducible promoters: one in front of the *galC* gene and one in front of the *galA* gene. In order to determine the transcription start site of these presumed *gal*A and *gal*C promoters, primer extension analysis was performed using RNA extracted from *B. breve* UCC2003 grown in Modified Rogosa medium containing 0.5% galactan as the sole carbohydrate source. Two extension products were identified 92 and 93 nucleotides 5′ to the predicted translational start site for the *gal*A gene, while for the *gal*C gene two transcription initiation sites were observed 234 and 235 bp upstream of its predicted translational start site ([Fig. 5](#f5){ref-type="fig"}). Analysis of the *gal*C promoter regions revealed potential promoter recognition sequences resembling consensus −10 and −35 hexamers, while for the *galA* promoter a clear −10 sequence could be identified, with no obvious −35 sequence present within the expected range of this −10 sequence although a potential −35 sequence is present further upstream ([Fig. 5](#f5){ref-type="fig"}).

![Schematic representation of the *B. breve* UCC2003 *galA* (panel A I) and *galC* (panel B I) promoter regions. Boldface type and underlining indicate the −10 and −35 hexamers as deduced from the primer extension results (Panel A II‐*gal*A and B II‐*gal*C) and ribosomal binding site (RBS); the transcriptional start sites (TSS) are indicated by asterisks; arrows under sequence in bold indicate the inverted repeat sequence that represents the GalR binding sequence. The inverted repeat sequences *gal*AIR1 and IR2 and *gal*CIR1 and IR2 are indicated as broken thick black line underneath the respective sequences.](mbt0004-0403-f5){#f5}

GalR binds to the *galC* and *galA* promoter regions
----------------------------------------------------

The presence of *gal*R, encoding a putative LacI‐type regulator within the endogalactanase gene cluster suggests that this gene is involved in the transcriptional regulation of the *gal* gene cluster as obvious from the microarray data ([Table 2](#t2){ref-type="table"}). In order to establish if GalR is capable of direct interaction with specific operators within the promoter region(s) of the *gal* gene cluster, we first cloned the *gal*R gene in the nisin‐inducible vector pNZ8150 with the introduction of a His‐tag‐encoding sequence to facilitate subsequent protein purification. The purified GalR protein was then used to perform electrophoretic mobility shift assays, which clearly demonstrate that the GalR protein can complex with IRD800‐labelled DNA fragments encompassing the *gal*A and *gal*C promoter regions ([Fig. 6B](#f6){ref-type="fig"}). Further delineation of the GalR recognition sequence suggested that GalR binding required an 85 bp DNA segment present within the *gal*A and *gal*C promoter regions ([Fig. 6A](#f6){ref-type="fig"}). Inspection and comparison of these two 85 bp fragments revealed the presence of two inverted repeats in each fragment, which represent putative operator sequences for the GalR protein. This notion was further validated by electrophoretic mobility shift assays using 34 bp DNA fragments that just contained the predicted operator sequences ([Fig. 6C](#f6){ref-type="fig"}). Introduction of two point mutations in the putative GalR‐binding motif (a T‐C and a G‐A mutation at positions five and six in [Fig. 6C](#f6){ref-type="fig"}) that are highly conserved in the motif were shown to significantly reduce binding of GalR (results not shown). To investigate whether GalR interaction with its target DNA sequence is influenced by a carbohydrate effector molecule, as is known for other LacI‐type regulators (reviewed by [@b40]; [@b32]), several carbohydrates were tested for their effects on GalR--DNA complex formation. The results obtained clearly demonstrate that the binding ability of GalR for the g1 fragment of the *gal*A promoter region is completely lost in the presence of galactobiose at concentrations ranging from 20 mM to 2 mM ([Fig. 6D](#f6){ref-type="fig"}), whereas under the same experimental conditions lactose or galactose did not affect GalR binding to its target sequence (results not shown).

![Panel A: Representation of the *B. breve* UCC2003 endogalactanase operon and DNA fragments used in electrophoretic mobility shift assays (EMSAs) for the *galC* and *gal*A promoter resions. Plus and minus signs indicate whether or not GalR was able to bind to the particular DNA fragment respectively. Panel B: EMSA showing GalR interaction with DNA fragments encompassing fragment g1 and sbp1. Panel C: Alignment and web logo representation of predicted binding sequences of GalR together with EMSAs illustrating GalR interaction with galCIR1, galCIR2 and mutated derivatives mu‐galCIR1 and mu‐galCIR2. In each panel lane X represents a binding reaction to which no protein was added, while the remaining lanes represent binding reactions with the respective DNA probes incubated with increasing amounts of GalR (concentrations ranging from 0.04 nM 0.01 µM). Each successive lane, from right to left, corresponds to a doubling in the concentration of GalR. Panel D: EMSA showing GalR interaction with the DNA fragment g1 with the addition of galactobiose at concentrations ranging from 20--2 µM.](mbt0004-0403-f6){#f6}

Discussion
==========

Bifidobacteria rapidly colonize the intestine of infants during the first days to weeks of life. In breast‐fed infants *B. breve* is a frequently detected species followed by *B. infantis*, *B. longum* and *B. bifidum* ([@b30]; [@b11]). Differential capacities for complex carbohydrate utilization have been observed for different bifidobacteria and several studies have demonstrated that bifidobacteria dedicate a significant portion of their coding capacity to the metabolism of a wide variety of carbohydrates ([@b31]; [@b35; @b36]). Over 50 different bifidobacterial carbohydrases have been described in the literature to date (reviewed by [@b34]). Using *B. breve* UCC2003 as a model to study bifidobacterial carbohydrate metabolism, we previously characterized an operon encoding a β‐fructofuranosidase ([@b29]), an extracellular amylopullulanase that hydrolyses α‐1,4 and α‐1,6 glucosidic linkages in starch and related polysaccharides ([@b28]; [@b20]), two novel α‐glucosidases exhibiting hydrolytic activities towards panose, isomaltose, isomaltotriose and trehalose ([@b25]), and a gene cluster dedicated to ribose metabolism ([@b24]). In addition, a PEP‐PTS system involved in fructose metabolism was identified and studied in this bacterium ([@b16]).

In this study, we describe the functional characterization of a locus dedicated to the utilization of galactan by *B. breve* UCC2003. The *gal*A gene of *B. breve* UCC2003 was previously shown to be involved in the degradation of potato galactan ([@b21]) and is presumed to encode an extracellular β‐1,4‐endogalactanase. The data presented here establish that galactotriose derived from this endogalactanase activity is specifically transported to the cytoplasm through an ABC transport system, which is specified by the gene products of *galCDE*, and that galactotriose is then degraded to galactose by a dedicated intracellular β‐galactosidase, encoded by *galG*. The galactose is then presumed to be fed into the fructose‐6‐phosphate phosphoketolase pathway via the Leloir pathway, thereby allowing *B. breve* UCC2003 to use galactan as a sole carbon and energy source.

In line with the findings described previously for *B. longum* NCC490 ([@b10]), the purified GalA from *B. breve* UCC2003 liberates predominately galactotriose from galactan with very small amounts of galactobiose and galactose being produced. In addition, through construction of a UCC2003 *gal*A insertion mutant that separates the GH53‐encoding domain from its C‐terminal domain, as well as purification of a truncated version of GalA (GalAT) we demonstrate that only the GH53 domain of GalA is essential for galactan metabolism to galactotriose. [@b10]) hypothesized that GalA functions by means of a processive mechanism; initially, the galactan undergoes a mid chain or endo cleavage, allowing the enzyme to remain attached to one end of the cleaved galactan chain, after which it liberates galacto‐oligosaccharides in an exo‐fashion. The authors speculate that the C‐terminal extension may play a role in forming a fold over the catalytic site and maintaining galactan at the catalytic site for multiple cleavage events. This substrate entrapment strategy may provide such galactan‐metabolizing bifidobacteria a selective advantage in the highly complex and competitive environment of the gut.

To investigate the involvement of the ABC transporter encoded by *galCDE* and the β‐galactosidase specified by *gal*G in galactan metabolism, insertion mutants were created in *gal*C, the first gene of the ABC transporter, specifying the substrate‐binding protein and *gal*G. In contrast to the parent strain UCC2003, the *galC* and *galG* mutant strains were no longer able to grow on galactan, thereby establishing that the ABC transporter and β‐galactosidase encoded by the *gal* locus are dedicated towards galactotriose transport and metabolism.

The deduced protein GalR is related to members of the LacI‐type regulatory protein family and our results obtained with the purified GalR protein are consistent with its role as a transcriptional regulator of the *gal* locus. Two GalR binding sites each were found to be present in 85 bp regions of the *gal*A and *gal*C promoter regions. The sequence required for recognition of GalR was shown to be a 9 bp inverted repeat, for each promoter region the two inverted repeat sequences overlap the −10 and −35 promoter recognition sequences. Most members of the LacI family bind carbohydrate or nucleoside effectors, which modulate their binding properties ([@b40]; [@b32]). Our results demonstrate that GalR--DNA interaction was lost in the presence of low concentrations of galactobiose, and was not affected by the presence of lactose or galactose. Because it is not commercially available, we did not test the effect of galactotriose, but we predict that, as galactotriose is the predominant product of endogalactanase activity, this trisaccharide also abolishes the GalR--DNA interaction. Therefore, it is presumed that galactotriose or galactobiose, and perhaps other β‐1,4 galacto‐oligosaccharides, are inducers of the *gal* operon, as they promote release of GalR from the operator sequences upstream of *gal*C and *gal*A. In the absence of galactotriose/biose, GalR is presumed to bind to its operator sites thereby blocking transcription of the *gal* genes. This simple control mechanism through negative regulation of transcription appears to be common in bifidobacteria ([@b22; @b23]; [@b25]; [@b37]) allowing these bacteria to quickly and efficiently respond to the presence of particular carbohydrates.

Fermentation of complex carbohydrates in the gut is assumed to be a result of the combined action of several bacteria ([@b41]). However, knowledge on how individual intestinal species of bacteria utilize complex poly‐ and oligosaccharides is limited, despite its importance for our understanding of the various metabolic activities that take place in the colon. The data presented here illustrate that the ability to metabolize the plant‐derived polysaccharide galactan is not ubiquitous among bifidobacteria or indeed *B. breve* strains. While certain components of the *B. breve* UCC2003 *gal* locus, i.e. those that specify the ABC transporter system, the β‐galactosidase and the GalR regulator, were present in all tested *B. breve* strains, a clear correlation was found between the presence of the endogalactanase gene and the (in)ability of such individual strains to grow on galactan as a sole carbohydrate source. Therefore, in the gastrointestinal environment we speculate that bifidobacterial strains lacking endogalactanase activity can still metabolize the galactotriose that is generated by extracellular endogalactanase activity of other bacteria, because of the retention of genes specifying the galactotriose ABC transporter and β‐galactosidase.

Interestingly, we observed that bifidobacterial strains that can metabolize galactan have a preference for β‐1,4‐linked galactans derived from potato (tubers), while none of the strains we examined in this study could grow to an appreciable level on arabinogalactan derived from larch wood that comprises β‐1,3‐linked galactose units. The ability of probiotic strains to ferment particular oligo‐ and polysaccharides has been the basis for selection as prebiotics. The observed preference for galactan containing predominantly β‐1,4 galactose units by the bifidobacterial strains tested here may have application in the development of targeted bifidogenic galacto‐oligosaccharides for specific probiotic strains using single or combinations of bifidobacterial β‐galactosidases. The incorporation of such galacto‐oligosaccharides in foods has potential for the development of novel functional foods or infant food formulas. Our previous studies on starch metabolism established that *B. breve* UCC2003 produces an extracellular starch‐degrading enzyme, ApuB, which has a preference for starch derived from potatoes ([@b29]; [@b20]). It is particularly interesting to note that UCC2003 produces at least two extracellular enzymes that are dedicated to metabolize polysaccharides commonly found in potatoes, which in fact have only become the staple diet of Europeans since their introduction to Europe from Peru in the 16th century ([@b13]).

Experimental procedures
=======================

The description of the *Experimental procedures* resides in Appendix S1 in *Supporting information*.
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